Congenital analbuminemia is a rare genetic condition where the body makes little to no albumin, a key blood protein. Many people with congenital analbuminemia have few clear signs, but swelling in the legs or ankles and fatigue can occur. It is lifelong and usually recognized in infancy, childhood, or early adulthood, with newborns at higher risk for complications. Most people with congenital analbuminemia live a normal lifespan, though severity can vary. Treatment focuses on managing swelling, nutrition, and monitoring, and doctors may use albumin infusions in specific situations.
Overview
Congenital analbuminemiaSymptoms
Congenital analbuminemia causes few problems; early signs of congenital analbuminemia include swelling (edema) like puffy feet, ankles, or face, and sometimes low blood pressure, dizziness, and fatigue. Newborns may have widespread swelling, while many older children and adults feel well.
Outlook and prognosis
Most people with congenital analbuminemia live into adulthood, often without major day‑to‑day limits. Risks are highest in infancy and during pregnancy, when low albumin can stress the heart and circulation. Regular follow‑up and targeted care help prevent complications.
Causes and risk factors
Congenital analbuminemia results from changes in the ALB gene, inherited in an autosomal recessive pattern. Risk rises when both parents are carriers, especially with consanguinity; new mutations are rare. Illness, pregnancy, or dehydration can worsen early symptoms of congenital analbuminemia.
Genetic influences
Genetics are central in congenital analbuminemia; it’s almost always caused by changes in the ALB gene inherited in an autosomal recessive pattern. Carriers usually have no symptoms. Genetic testing and family screening can confirm the diagnosis and guide counseling for future pregnancies.
Diagnosis
Clinicians suspect congenital analbuminemia when routine blood tests show extremely low albumin with otherwise normal liver and kidney evaluations. They rule out protein loss, then confirm with ALB gene testing. Genetic diagnosis of congenital analbuminemia relies on sequencing or panels.
Treatment and drugs
Treatment for congenital analbuminemia focuses on supporting nutrition, maintaining fluid balance, and reducing strain on the circulatory system. Care may include albumin infusions during illness or surgery, salt restriction, diuretics if swelling occurs, and careful pregnancy monitoring. Regular follow-up helps tailor therapy.
Symptoms
Fluid can build up in soft tissues, so daily life may include swelling that comes and goes. For some, the early features of congenital analbuminemia are subtle—ankles that puff by evening or a belly that feels fuller than usual. Features vary from person to person and can change over time. Many feel well for years and only learn about it when routine blood tests show very low albumin with high cholesterol or triglycerides.
Puffiness of the ankles, feet, hands, or face can appear, especially after standing or at day’s end. Pressing a finger may leave a small dent that slowly fades. Swelling can ease overnight when legs are elevated.
Fluid can collect in the belly (ascites), making the waistline expand or clothes feel tighter. People with congenital analbuminemia may feel bloated, heavy, or full sooner when eating. Mild discomfort or back pressure can come with this fullness.
If fluid builds around the lungs, breathing can feel harder with activity or when lying flat. A dry cough or chest heaviness may show up until the fluid is treated.
Blood tests often show high cholesterol and triglycerides because albumin helps carry fats. Some people develop small, yellowish patches on the eyelids or skin from fat deposits. Clinicians call this xanthelasma, which means cholesterol-rich spots in the skin.
How people usually first notice Congenital analbuminemia?
Many families never notice anything right away because newborns with congenital analbuminemia often look healthy, and routine hospital checks don’t measure albumin. The first signs of congenital analbuminemia are usually found later when a blood test done for swelling, fatigue, or during a checkup shows extremely low or undetectable albumin despite normal liver and kidney tests. In some babies and children, doctors may first notice poor weight gain, ankle swelling, or foamy urine, which prompts testing and leads to the diagnosis.
Types of Congenital analbuminemia
Congenital analbuminemia is a rare genetic condition where the body makes very little or no albumin, a key blood protein. Variants of this condition are defined by different changes in the ALB gene, which can affect how much albumin is produced and how early symptoms show up. Not everyone will experience every type. Clinicians often describe them in these categories:
Null mutations
These variants stop albumin production almost completely. People may have very low albumin from birth with swelling, low blood pressure, and lipid changes. Early symptoms of congenital analbuminemia can be more noticeable in newborns and during pregnancy.
Missense mutations
These changes alter a single building block of albumin and can reduce its stability or function. Albumin levels are often very low but sometimes detectable, and symptoms may be milder. Some may notice issues under stress, illness, or during growth spurts.
Splice-site mutations
These variants disrupt how the ALB gene’s message is processed. Albumin levels are typically extremely low because the protein is misassembled or truncated. Severity can vary depending on how much normal message still gets made.
Nonsense-mediated escape
Rarely, certain changes allow a small amount of albumin to be made despite a stop signal. People may have trace albumin and fewer symptoms at rest. Strain such as infection or surgery can unmask swelling or fatigue.
Founder mutations
In some families or regions, a shared ALB change is seen across many relatives. The clinical picture often mirrors the specific underlying variant, from severe to milder forms. Discussing the exact genetic change can clarify expected symptom patterns and family testing.
What genetics can tell you about symptoms
People with congenital analbuminemia, caused by changes in the ALB gene that drastically lower albumin, may have swelling in the legs or face, fatigue, and low blood pressure, especially during illness or pregnancy. Some newborns show jaundice, while adults can develop high cholesterol and muscle aches.
Causes and risk factors
Congenital analbuminemia results from harmful changes in the ALB gene that leave the body with little or no albumin.
You develop it when you inherit two nonworking copies, one from each parent.
The main risk factors for congenital analbuminemia are having two carrier parents and parents who are closely related.
Doctors distinguish between risk factors you can change and those you can’t.
Illness, poor nutrition, dehydration, or pregnancy can make symptoms more noticeable, but they do not cause the condition.
Environmental and biological risk factors
For congenital analbuminemia, risk relates almost entirely to internal biology present before birth. Doctors often group risks into internal (biological) and external (environmental). Most research has not found outside exposures that change the chance of this condition. Risk factors don’t predict early symptoms of congenital analbuminemia, but they can help explain why it shows up from the start of life.
The body’s albumin-making process is set very early in fetal development. This internal biology determines whether the condition is present. It is not driven by events during labor or delivery.
Advanced maternal or paternal age does not appear to raise the chance of congenital analbuminemia. Cases are reported across a wide range of parent ages.
No consistent link has been found between common pregnancy health conditions and the condition. It has been seen after otherwise healthy pregnancies as well as complicated ones.
No specific environmental exposures have been shown to increase risk. Available reports do not tie radiation, heavy metals, or air pollution to higher likelihood.
Genetic risk factors
This condition stems from changes in a single gene (ALB) that are passed down in an autosomal recessive pattern. In congenital analbuminemia, a child inherits two nonworking copies—one from each parent—leading to extremely low albumin levels. Carrying a genetic change doesn’t guarantee the condition will appear, because one working copy is usually enough. Some families or communities may see more cases due to a shared ancestor with the same change.
ALB gene variants: Changes in the ALB gene stop the body from making normal albumin. Many changes truncate the protein or disrupt how the gene’s message is processed.
Autosomal recessive: Two altered copies are required for congenital analbuminemia to develop. People with one altered copy are carriers and typically have no symptoms.
Carrier parents risk: When both parents are carriers, each pregnancy has a 25% (1 in 4) chance of an affected child. There is a 50% (1 in 2) chance the child will be a healthy carrier.
Family history: Having an affected sibling or a known ALB variant in the family raises the likelihood of congenital analbuminemia. Targeted genetic testing can clarify who in the family carries the same change.
Founder variants: Some communities share an ancestor with the same ALB change, making congenital analbuminemia more likely in those groups. This founder effect can lead to multiple cases within extended families.
Parental relatedness: Parents who are closely related are more likely to carry the same rare ALB change. This increases the chance their children inherit two altered copies.
Genetic testing: Sequencing the ALB gene can confirm the diagnosis and identify the exact variant in a family. Knowing the family variant allows testing of relatives before any early symptoms of congenital analbuminemia appear.
Variant type impact: Different ALB changes can alter how much albumin is produced, from trace amounts to nearly none. This may help explain why features vary between people with congenital analbuminemia.
Lifestyle risk factors
Congenital analbuminemia is a genetic condition; lifestyle habits do not cause it, but they can influence edema, lipid levels, and day‑to‑day comfort. When people mention lifestyle risk factors for Congenital analbuminemia, they are really talking about choices that can worsen or ease swelling and metabolic issues. Small adjustments in diet, hydration, movement, and daily routines may help manage symptoms and reduce complications. Work with your clinical team to individualize these strategies.
High‑salt meals can increase fluid retention and ankle swelling because low albumin reduces oncotic pressure. Reducing sodium often lessens edema and blood pressure swings.
Rapidly drinking large volumes can worsen swelling by shifting more fluid into tissues. Steady, moderate hydration helps minimize fluid shifts and discomfort.
Extra protein will not restore albumin, but adequate protein supports other plasma proteins that partly compensate. Very low‑protein diets can aggravate fatigue, edema, and slow healing.
People with analbuminemia often have high cholesterol or triglycerides; limiting saturated fats and refined carbs can improve these levels. Emphasizing unsaturated fats and soluble fiber supports lipid control.
Risk prevention
Congenital analbuminemia can’t be fully prevented because it’s a genetic condition present from birth, but you can reduce complications and stay ahead of problems. Planning, routine checkups, and careful medication choices make a meaningful difference in daily life. Even if you can’t remove all risks, prevention can reduce their impact. Work with a care team familiar with congenital analbuminemia to tailor steps for your age, health, and plans, including pregnancy.
Meet with a genetics professional to understand inheritance and carrier testing options. This can guide family planning and help identify relatives who may be affected.
If congenital analbuminemia runs in your family, ask about carrier screening for partners or siblings. Results can inform pregnancy planning and early monitoring.
Plan pregnancy with a high‑risk obstetrics team experienced in congenital analbuminemia. Close monitoring helps manage swelling, blood pressure, and medicine dosing during pregnancy.
Some medicines bind to albumin and can act stronger when albumin is very low. Have every new prescription and anesthesia plan checked so doses are adjusted safely.
Transmission
Congenital analbuminemia is not contagious; it cannot be caught or spread through contact. It is a genetic condition passed down in an autosomal recessive pattern. This means a child must inherit two nonworking copies of the albumin gene—one from each parent—to have the condition; parents with a single nonworking copy are healthy carriers. When both parents are carriers, each pregnancy has a 25% (1 in 4) chance of a child having the condition, a 50% (1 in 2) chance of a child being a carrier, and a 25% chance of neither. Occasionally, a new change in the gene can be involved, but most cases happen when both parents are carriers—the most common route is the genetic transmission of congenital analbuminemia within families.
When to test your genes
Consider genetic testing if you have extremely low blood albumin with no clear cause, a family history of analbuminemia, or unusually mild symptoms despite very low albumin on lab tests. Testing confirms the diagnosis, guides care during illness, surgery, or pregnancy, and informs family screening. Discuss timing with a genetics professional to align with your health plans.
Diagnosis
Congenital analbuminemia is usually suspected when routine blood work shows very low or nearly absent albumin, often in someone with mild swelling or no obvious symptoms. Doctors usually begin with a review of symptoms, a physical exam, and repeat lab tests to confirm the pattern. The genetic diagnosis of Congenital analbuminemia typically relies on ruling out more common causes of low albumin and then confirming a change in the albumin gene. Some diagnoses are clear after a single visit, while others take more time.
Clinicians ask about swelling, fatigue, past illnesses, and any relatives with very low albumin. A careful history helps point toward a rare inherited cause rather than kidney, liver, or gut problems.
The exam looks for ankle or facial puffiness, soft-tissue swelling, and other visible signs. Many living with congenital analbuminemia have few outward features between episodes.
Blood tests show very low or undetectable albumin on repeated checks. If results are unexpected, labs may use an immunoassay because some dye-based methods can read falsely low at extreme levels.
A laboratory study separates blood proteins and typically shows a missing or tiny albumin band. Other proteins may be higher than usual, which can partly offset the total protein level.
Stages of Congenital analbuminemia
Congenital analbuminemia does not have defined progression stages. It’s present from birth and tends to be lifelong, with symptoms that vary from person to person rather than following a steady stepwise decline; for some, early symptoms of congenital analbuminemia include body swelling in infancy, while later issues may involve fatigue or high cholesterol. Different tests may be suggested to help confirm the cause and rule out liver or kidney disease. Diagnosis usually relies on blood tests showing very low albumin together with genetic testing of the albumin gene, and ongoing monitoring focuses on cholesterol levels, swelling, and overall nutrition.
Outlook and prognosis
Looking at the long-term picture can be helpful. Many people with congenital analbuminemia grow up without obvious symptoms, and the diagnosis is sometimes found incidentally on routine blood work. Others notice swelling in the legs or around the eyes after long days on their feet, fatigue during infections, or trouble tolerating certain medications. The outlook is not the same for everyone, but careful monitoring usually keeps day-to-day life fairly stable.
Prognosis refers to how a condition tends to change or stabilize over time. In childhood, congenital analbuminemia can raise risks during illness because albumin helps keep fluid balanced and carries hormones and drugs; newborns may be more vulnerable to infections and jaundice, and a few severe cases have been linked with infant loss. Past early childhood, most people with congenital analbuminemia have a near-normal life span, though they may face higher chances of swelling, low blood pressure with dehydration, or medication side effects. Some people experience frequent ankle swelling and repeated hospital visits during infections, while others notice only mild issues a few times a year.
With ongoing care, many people maintain good health and active routines. Managing triggers, addressing early symptoms of congenital analbuminemia such as new swelling or dizziness, and reviewing medications that rely on albumin for transport can lower complications. In medical terms, the long-term outlook is often shaped by both genetics and lifestyle. Talk with your doctor about what your personal outlook might look like.
Long-term effects
For many, day-to-day life is fairly typical between occasional flares of swelling or fatigue. Congenital analbuminemia often stabilizes after infancy as the body boosts other blood proteins to partly compensate. Long-term effects vary widely, with some people feeling well for years and others noticing intermittent issues during illness, stress, or pregnancy. Over time, daily routines may change a bit—like wearing compression socks on travel days or planning around medical appointments when needed.
Ongoing low blood protein can make ankles, legs, or the face swell from time to time. Flares may show up during infections, after long flights, or in pregnancy.
Many people develop high cholesterol and triglycerides over time. This pattern often appears in adolescence or adulthood and may raise long-term heart risk.
Drugs that usually ride on albumin can act stronger or wear off faster. Anesthetics, pain medicines, and some antibiotics may behave unpredictably without this carrier protein.
Swelling and blood pressure shifts can be more pronounced in pregnancy. Care often needs closer monitoring to support both parent and baby.
How is it to live with Congenital analbuminemia?
Living with congenital analbuminemia often means feeling generally well but needing extra attention during illness, surgery, or pregnancy, when the body’s low albumin reserve can make fluids shift and medications behave unpredictably. Day to day, many people manage with periodic labs, hydration awareness, and careful review of new prescriptions, since protein binding affects drug dosing. For families, the condition can prompt genetic conversations because it is inherited, and partners or caregivers may learn to watch for swelling, fatigue, or signs of dehydration and seek care early. With a knowledgeable care team and a plan for medical procedures or acute illnesses, most people lead full lives while staying ahead of the higher‑risk moments.
Treatment and drugs
Treatment for congenital analbuminemia focuses on easing symptoms and preventing complications, since there’s no way to replace albumin long term through the body’s own production. Many people with congenital analbuminemia do well with careful monitoring, nutrition support, and medications to manage swelling, cholesterol, and blood pressure; doctors may also advise avoiding dehydration and certain drugs that bind strongly to albumin. In situations like surgery, severe infection, pregnancy complications, or marked swelling, short-term albumin infusions and diuretics may be used in the hospital to stabilize fluid balance. Treatment plans often combine several approaches, and specialists may check children’s growth, adults’ cardiovascular risk, and in pregnancy, the baby’s well-being. Keep track of how you feel, and share this with your care team, as doses and choices may change over time.
Non-drug treatment
Living with congenital analbuminemia can mean swelling, fatigue, and needing a plan for travel, illness, or surgery. Day-to-day care focuses on protecting fluid balance, supporting nutrition and growth, and lowering strain on the heart and circulation. Non-drug treatments often lay the foundation for long-term stability. Care plans are tailored by age and life stage, especially for children and during pregnancy.
A dietitian can help ensure enough protein and calories to support growth and healing. Guidance also helps space meals and snacks to avoid long fasting, which may worsen fatigue or dizziness.
Limiting excess salt can reduce fluid buildup and ankle swelling. Your care team may advise a steady, moderate fluid intake rather than big swings across the day.
Graduated compression socks or stockings can help move fluid back into circulation and ease leg swelling. Proper fit matters, so a clinician or fitter should size and teach safe use.
Gentle, regular walking or swimming supports circulation and reduces dependent swelling. Short movement breaks on long flights or desk days can help prevent fluid pooling.
Your genes may have an impact on how drugs work for you
Even without albumin, people metabolize medicines differently because liver enzymes and transport proteins are partly set by their genes. Pharmacogenetic testing can sometimes guide safer dosing, especially for drugs with narrow safety windows or strong protein-binding.
Pharmacological treatments
Most people with congenital analbuminemia don’t need daily medication, but short-term treatment is sometimes used during illness, surgery, pregnancy, or in infancy when symptoms flare. The main goals are to ease swelling, support circulation, and manage the often high cholesterol and triglycerides that come with this condition. Sometimes medicines are taken short-term (acute treatment), while others are used long-term (maintenance therapy). Your care team will tailor choices to your age, symptoms, and lab results.
Intravenous human albumin (5% or 20%) can be given in the hospital to raise blood protein temporarily. This may help relieve swelling and support blood pressure, including in newborns with early symptoms of congenital analbuminemia like puffiness or breathing trouble. Doctors monitor fluid balance closely during and after infusions.
Atorvastatin or rosuvastatin may be used to lower LDL cholesterol, which often runs high in congenital analbuminemia. First-line medications are those doctors usually try first, based on how well they lower risk and their safety profile. Your team will check liver enzymes and ask about muscle aches.
Fenofibrate or gemfibrozil can lower high triglycerides, sometimes used if triglycerides stay elevated despite lifestyle steps. These may be used alone or carefully with a statin when both LDL and triglycerides are high. Your clinician will watch for muscle symptoms and adjust dosing if needed.
Prescription omega-3s such as icosapent ethyl or omega-3 acid ethyl esters can further reduce triglycerides. These are typically add-on options when triglycerides remain high after other measures. They can slightly raise LDL in some people, so follow-up labs matter.
Genetic influences
In most families, congenital analbuminemia happens when a child inherits two altered copies of the same gene (called ALB), which the body uses to make albumin, a major protein in the blood. This “autosomal recessive” pattern means each parent usually carries one changed copy and feels well, while a child who receives both changed copies has very low or absent albumin. DNA testing can sometimes identify these changes. If both parents are carriers, each pregnancy has a 25% chance of a child with congenital analbuminemia, a 50% chance of a carrier, and a 25% chance of a child with no gene changes. The impact can vary widely: some people with congenital analbuminemia do quite well because other blood proteins partly compensate, but newborns and pregnant women may face more challenges. Genetic counseling can clarify family risks and who else might consider testing, especially if early symptoms of congenital analbuminemia have raised questions.
Is Congenital analbuminemia genetic?
Genetics are central in congenital analbuminemia; it’s almost always caused by changes in the ALB gene inherited in an autosomal recessive pattern. Carriers usually have no symptoms. Genetic testing and family screening can confirm the diagnosis and guide counseling for future pregnancies.
Pharmacogenetics—how genetics influence drug effects
Because congenital analbuminemia comes from inherited changes in the albumin gene, there is little or no albumin in the blood. Albumin normally carries many medicines; when it’s missing, a larger share of certain drugs stays “free” in the bloodstream, which can make effects stronger and side effects more likely. This is especially relevant for medicines that are usually highly albumin‑bound, such as warfarin, phenytoin, diazepam, and some anti‑inflammatory pain relievers (NSAIDs), while some water pills like furosemide may work less well without albumin to help deliver them to the kidney.
For safe medication choices in congenital analbuminemia, clinicians often start with lower doses, choose alternatives with lower protein binding when possible, and monitor active drug levels and your day‑to‑day response closely. Alongside medical history and lab tests, genetic testing can sometimes identify how your body handles certain medicines that are processed by the liver, which can help fine‑tune dosing. Because needs vary, plan care with a pharmacist and doctor who can watch for interactions and adjust doses during illness, pregnancy, or surgery.
Interactions with other conditions
People living with congenital analbuminemia often notice that swelling and fatigue get worse during other illnesses that lower protein levels, such as kidney or liver disease. A condition may “exacerbate” (make worse) symptoms of another. For example, a flare of kidney problems or an infection can further drop blood protein, leading to more leg or abdominal swelling and sometimes shortness of breath. Early symptoms of congenital analbuminemia can also look like nephrotic syndrome or severe liver disease, so overlaps may delay a clear diagnosis.
Because albumin normally carries fats in the blood, many have high cholesterol; when heart disease or diabetes is also present, cardiovascular risk can climb and warrants close monitoring. Pregnancy needs extra attention, since fluid shifts and blood pressure changes can intensify swelling and strain the circulation. If bone or mineral problems exist, low total calcium readings from low albumin can be confusing, so doctors may check “ionized” calcium to see the true level. Talk with your doctor about how your conditions may influence each other, especially during infections, surgery, or pregnancy, when careful, coordinated care helps keep symptoms steady.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
History
Throughout history, people have described families in which several relatives seemed “remarkably slim” or fatigued despite eating well, and babies who struggled to gain weight but didn’t fit common diagnoses. Looking back, these stories likely included congenital analbuminemia, a very rare condition present from birth that leads to extremely low levels of albumin, the main protein in blood.
First described in the medical literature as an unusual absence of serum albumin in the mid-20th century, early reports came from adults who appeared surprisingly well despite lab tests showing almost no albumin. Doctors were puzzled because albumin was known to help maintain fluid balance and carry hormones and medicines. Initially understood only through symptoms, later studies showed that other blood proteins can partially “step in,” which helps explain why many people with congenital analbuminemia reach adulthood before it’s found. At the same time, providers also noticed that newborns with the condition can have more serious issues, including swelling and trouble feeding, highlighting important differences between infants and adults.
In recent decades, knowledge has built on a long tradition of observation. As medical science evolved, researchers traced the condition to changes in the gene that directs albumin production. Careful family studies revealed autosomal recessive inheritance, meaning it typically appears when both parents carry a silent copy of the changed gene. These findings matched older family patterns people had noticed but couldn’t explain at the time.
With each decade, improved lab testing made it easier to measure albumin accurately and to rule out other causes of low albumin, such as kidney, liver, or gut conditions. Genetic testing then confirmed the diagnosis in suspected cases and clarified that congenital analbuminemia is rare worldwide, with some regions reporting more cases due to shared ancestry. The way the condition was viewed shifted from a medical curiosity to a recognized, lifelong but often manageable diagnosis.
From early theories to modern research, the story of congenital analbuminemia illustrates how patient stories, careful clinical observation, and advances in genetics come together. Knowing the condition’s history helps explain why some adults are found only after routine blood work, while early symptoms of congenital analbuminemia in infants may prompt closer monitoring. Today, this background guides more accurate diagnosis, better counseling for families, and thoughtful care across the lifespan.